

Haematologica
HAEMATOL/2018/207118
Version 4

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

Marie Sébert, Aline Renneville, Cécile Bally, Pierre Peterlin, Odile Beyne-Rauzy, Laurence Legros, Marie-Pierre Gourin, Laurence Sanhes, Eric Wattel, Emmanuel Gyan, Sophie Park, Aspasia Stamatoullas, Anne Banos, Kamel Laribi, Simone Jueliger, Luke Bevan, Fatiha Chermat, Rosa Sapena, Olivier Nibourel, Cendrine Chaffaut, Sylvie Chevret, Claude Preudhomme, Lionel Adès, and Pierre Fenaux

Disclosures: The GFM received an Unrestricted grant from Astex to conduct the study

Contributions: M.S., P.F. and L.A. conceived the study; M.S. and P.F. drafted the manuscript; A.R., O.N. and C.P performed molecular analysis; M.S., L.A., P.F., C.B., P.P., O.BR, L.L., MP.G., L.S., E.W., E.G., S.P., A.S., A.B. and K.L. included and treated patients, S.J. and L.B. performed methylation analysis, F.C. and R.S. collected data, C.C. and S.C. did the statistical analysis; all contributing authors approved the manuscript.